SCHEMBL6522692

SCHEMBL6522692

O=c1[nH]c2nccc(NC3CCNCC3)c2c2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 15/20 0.56
AURKB Q96GD4 11/20 0.53
ROCK2 O75116 1/20 0.48
ROCK1 Q13464 1/20 0.48
CDC42BPB Q9Y5S2 1/20 0.48
MAPK13 O15264 1/20 0.47
CHEK2 O96017 1/20 0.47
NTRK1 P04629 1/20 0.47
RET P07949 1/20 0.47
HCK P08631 1/20 0.47
FGFR1 P11362 1/20 0.47
FLT4 P35916 1/20 0.47
LIMK1 P53667 1/20 0.47
SIK1 P57059 1/20 0.47
TNK2 Q07912 1/20 0.47
WNK3 Q9BYP7 1/20 0.47
PARP1 P09874 1/20 0.46
JAK1 P23458 1/20 0.45
UTS2R Q9UKP6 2/20 0.44
BRD4 O60885 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13680299 0.93 AURKA (0.54) AURKAAURKBROCK2ROCK1CDC42BPB
SCHEMBL6532632 0.79 ROCK2 (0.53) AURKAAURKBROCK2ROCK1JAK1
SCHEMBL6522039 0.79 AURKA (0.50) AURKAAURKBMAPK13CHEK2NTRK1
SCHEMBL6526955 0.79 AURKA (0.47) AURKAAURKBROCK2ROCK1MAPK13
SCHEMBL6530953 0.76 AURKA (0.45) AURKAAURKBMAPK13CHEK2NTRK1
SCHEMBL6518798 0.76 AURKA (0.54) AURKAAURKBMAPK13CHEK2NTRK1
SCHEMBL6531373 0.76 GRIN2B (0.49) AURKAAURKBMAPK13CHEK2NTRK1
SCHEMBL6520619 0.76 AURKA (0.49) AURKAAURKBROCK2ROCK1MAPK13
SCHEMBL12634152 0.75 KMT5B (0.49) ROCK2ROCK1CDC42BPB
SCHEMBL3464852 0.75 AURKA (0.65) AURKAAURKBMAPK13CHEK2NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 AURKA 538/4885AURKB 487/4885ROCK2 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.